Idexx Laboratories (IDXX) EBIT (2009 - 2026)

Idexx Laboratories (IDXX) has reported EBIT for 18 consecutive years, with $362.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBIT rose 14.55% year-over-year to $362.6 million; the TTM figure through Mar 2026 stood at $1.4 billion (up 22.7% YoY), while the FY2025 annual figure was $1.4 billion, up 20.53% from the prior year.
• EBIT came in at $362.6 million for Q1 2026 at Idexx Laboratories, up from $315.6 million in the prior quarter.
• The five-year high for EBIT was $373.0 million in Q2 2025, with the low at $179.1 million in Q2 2022.
• Average EBIT over 5 years is $285.1 million, with a median of $280.4 million recorded in 2023.
• Across the five-year window, EBIT sank 30.93% in 2022 and jumped 65.38% in 2023, its largest moves.
• Year by year, EBIT stood at $226.5 million in 2022, then gained by 8.29% to $245.3 million in 2023, then grew by 6.68% to $261.7 million in 2024, then rose by 20.6% to $315.6 million in 2025, then gained by 14.89% to $362.6 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered $362.6 million, $315.6 million, and $354.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.